You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 265 No. 16, April 24, 1991 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Grand Rounds at the Clinical Center of the National Institutes of Health
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (14)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Recent Approaches to the Treatment of Sickle Cell Anemia

Griffin P. Rodgers, MD

JAMA. 1991;265(16):2097-2101.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

SELECTED CASE

A 35-YEAR-OLD man whose sickle cell anemia was first diagnosed at the age of 3 years was referred to the Clinical Center at the National Institutes of Health (NIH), Bethesda, Md, for evaluation and management of his disease. He had a history of frequent vaso-occlusive crises, skin ulcers, and recurrent bacterial pneumonias. He suffered a left hemispheric cerebrovascular accident at the age of 12 years and since then has had a residual seizure disorder. He regularly received transfusions every 3 months from ages 14 to 35 years and at the time of admission to the NIH had an estimated transfusion burden well in excess of 250 U. Other complications of his disease included proliferative sickle retinopathy and cardiomyopathy, which had led to worsening tolerance for exercise. His major complaint, however, was chronic pain in his knees, shins, back, elbows, and shoulders for which he required 4 mg of . . . [Full Text PDF of this Article]


Author Affiliations

From the Laboratory of Chemical Biology, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md.


Footnotes

Reprint requests to Laboratory of Chemical Biology, National Institute of Diabetes and Digestive and Kidney Diseases, Bldg 10, Room 9N-318, National Institutes of Health, Bethesda, MD 20892 (Dr Rodgers).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.